Revotar Biopharmaceuticals achieved positive results in Phase IIa Ozone Study with Bimosiamose for COPD. The study evaluated the effect of Bimosiamose on ozone-induced airway inflammation in healthy subjects with a new controlled breathing nebulizer device. The data supports further development of the new pan selectin antagonist in COPD. The trial was designed as a double-blind, placebo controlled, randomized cross-over study comprising 18 non-smoking healthy ozone-responsive volunteers. Each...